Disclaimer The recommendations presented in this study were developed using the RAND Corp methodology (Santa Monica, California)/ University of California-Los Angeles (RAND/ UCLA appropriateness method). Appropriateness ratings represent the best interpretation of the literature combined with expert judgment at the time of their development. The selection of a test ultimately lies with the physician and the assessment of multiple factors associated with the individual patient. The clinical scenarios used should not be considered inclusive of all situations in which a test/study should or can be performed. Future literature may require changes to the recommendations based on additional information.
| INTRODUCTION
Medical leaders and consumers are calling for a safer, more efficient and effective health care system. In recent years, there has been an exponential increase in the number of diagnostic tests. Given the increase in cost from new technologies, physicians need tools to help them make decisions about health care, especially in appropriateness of care, that achieve value, increase quality and control costs. 1 Appropriate use criteria (AUC) combine the best scientific evidence available with the collective judgment of experts to yield a statement of the appropriateness for performing a test in specific clinical scenarios encountered in everyday practice. Qualifying appropriateness is the first step in addressing cost-effectiveness as studies have shown good correlation between the two. 2 In 2015, the American Society of Dermatopathology (ASDP) created the AUC Task Force to help guide dermatopathologists in their use of ancillary studies. Four subgroups were established and each group chose 2 to 3 ancillary studies for which to develop AUC. The subgroups were divided into 4 broad categories: lymphoproliferative, melanocytic, soft tissue and other.
This report provides a synopsis of the AUC for the ancillary studies chosen by each of the subgroups and developed using the RAND/UCLA appropriateness method. 3 The goal in a health system is for inappropriate care to be reduced while necessary and appropriate care is increased or maintained. It is imperative to understand that the ancillary studies and clinical scenarios chosen are not exhaustive and that this publication is not a comparison of the different tests as each ancillary study was reviewed independently for each clinical scenario. In addition, as literature emerges updates to the AUC will need to be made and are already planned by the ASDP.
| MATERIALS AND METHODS
The AUC process combines evidence-based medicine with clinical scenarios and expert judgment by engaging a rating panel in a modified
Delphi exercise based on the validated appropriateness method of RAND/UCLA to yield a statement regarding the appropriateness of performing a test or procedure in a specific patient scenario. The process begins by selection of tests or procedures for which AUC will be created. In general, AUC focus on tests that are widely and frequently used, consume significant resources or have wide variations in their use. The process overview taken by the ASDP is outlined in (Figure 1 ).
In total, 12 dermatopathology ancillary studies underwent the COL1A1-PDGFB FISH assay in the diagnosis of dermatofibrosarcoma protuberans (DFSP) and dual-color break-apart EWSR1 FISH assay in differentiating melanocytic tumors and clear cell sarcoma (CSS).
| Development of definitions and clinical indications
Each of the 4 subgroups developed a set of definitions to clearly explain the meaning of assigned terms and histologic diagnoses as well as developed clinical scenarios ("indications") to simulate situations most likely to be encountered in clinical practice. A total of 211 clinical scenarios were produced and then reviewed independently for conciseness and completeness by 12 clinical indication reviewers composed of dermatopathologists from across the country with expertise in various areas. They were then modified accordingly such that they comprised the most often encountered situations in dermatopathology practice. The clinical scenarios were not intended to be exhaustive, but to represent at least 85% of anticipated scenarios. They were based on information that is readily available to dermatopathologists during routine practice (age, body site, histomorphology, etc.). Further specific information regarding definitions and clinical scenarios for each subgroup is summarized in Tables 1-7. 4-9
| Evidence
The development of AUC is founded on combining evidence review and analysis with expert judgment that is provided by the panel raters. A detailed literature review was performed by the AUC Task 1st round no interaction 2nd round in-person meeting followed by independent rating 3rd round conference call (2) followed by independent rating
Rarely appropriate Score 1-3 Uncertain appropriateness Score 4-6
Usually appropriate Score 7-9 annual ASDP meeting (Chicago, 2016) . During this meeting, there was a discussion of clinical scenarios where consensus had not been achieved.
The discussion was preceded by a literature review summary by an AUC Task Force member for each ancillary study for which AUC were being developed. The goal was to discuss the literature, draw from other experts in the field while also being mindful of not requesting ratings or influencing the panel to seek consensus. After the in-person meeting, the second-round rating was done individually and submitted to the research team within 2 weeks. Prior to the third-round rating, there were 2 moderated teleconference sessions, which focused on clinical scenarios that were close to consensus. Panel raters explored wording of clinical • Predominantly immunoreactive for CD2, CD3, CD4, CD5 and CD7 (partial) • Predominantly immunoreactive for CD4 or CD8 • Loss of 1 or more mature T-cell markers (CD2, CD3, CD5 and CD7) • "Concerning for," "suspicious of" or "suggestive of" mycosis fungoides: 1. Solitary or generalized scaly patches/plaques that are clinically concerning for mycosis fungoides (clinical impression: rule out mycosis fungoides or cutaneous T-cell lymphoma) and that are histologically and immunophenotypically "concerning for", "suspicious of" or "suggestive of" mycosis fungoides." 2. Clinical presentation of erythroderma with clinical impression of rule out mycosis fungoides, cutaneous T-cell lymphoma or Sézary syndrome and that is "not diagnostic for" mycosis fungoides. 3. Clinical presentation of dermatitis with clinical impression of rule out mycosis fungoides or cutaneous T-cell lymphoma and that is "not diagnostic for" mycosis fungoides. 4. Inflammatory/reactive papular or papulonecrotic eruption (solitary, regional or generalized) with clinical impression of LyP or PL, rule out mycosis fungoides or cutaneous T-cell lymphoma and histopathologic and immunophenotypic features typical for LyP or PL. 5. The development of T-cell cutaneous infiltrate that is "not diagnostic for" mycosis fungoides but is present in a patient with a history of mycosis fungoides with a known T-cell clone (comparison of past and present clones). 6. The development of a T-cell cutaneous infiltrate in a patient with a history of systemic T-cell lymphoma. 7. A cutaneous T-cell infiltrate with a folliculotropic rather than epidermotropic T-cell infiltrate. 8. Pigmented purpuric patches (solitary, regional or generalized) and clinical impression of rule out mycosis fungoides or cutaneous T-cell lymphoma and histopathologic and immunophenotypic features that are "not diagnostic for" mycosis fungoides. 9. Clinically reactive entities (see references for individual diagnoses) with histologically and immunophenotypically "concerning for," "suspicious of"
or "suggestive of" mycosis fungoides. 10. Preexisting diagnosis of mycosis fungoides and new or evolving lesions similar to original lesions with clinical impression of rule out mycosis fungoides in setting of preexisting mycosis fungoides and histopathologic and immunophenotypic features "consistent with" mycosis fungoides. 11. Development of nodules in a patient with mycosis fungoides which are histologically "concerning for," "suspicious of" or "suggestive of" large cell transformation with CD30 positivity. 12. Development of nodules in a patient with mycosis which are histologically "concerning for," "suspicious of" or "suggestive of" large cell transformation without CD30 positivity.
Abbreviations: PL, pityriasis lichenoides; LyP, lymphomatoid papulosis; WHO, World Health Organization.
scenarios or definitional understandings that needed clarification. Panel raters were also provided the statistical analysis based on results from the first and second rounds. The third and final ratings were completed individually, again within about 2 weeks of the teleconference sessions.
One panelist withdrew from the project after the first round; thus, the complete data for all 3 rounds were provided by 16 panel raters.
To facilitate the panel rater discussion and support categorization for each clinical scenario the mean of ratings was calculated; the mean was adjusted by filtering/removing 2 scores-the highest and lowest-to minimize the impact of outlying raters (mean'). A mean' of ≥7.0 was classified as "usually appropriate." A mean' of lymphoma, leg type) and that are histologically and immunophenotypically "concerning for," "suspicious of" or "suggestive of" cutaneous diffuse large B-cell lymphoma, leg type. 11. The development of a B-cell cutaneous infiltrate that is not diagnostic for cutaneous B-cell lymphoma in a patient with a history of cutaneous B-cell lymphoma with a known B-cell clone (comparison of past and present clones). 12. The development of a B-cell cutaneous infiltrate in a patient with a history of any systemic B-cell lymphoma. 13. Other more aggressive cutaneous B-cell lymphomas other than cutaneous diffuse large B-cell lymphoma, leg type, such as intravascular large B-cell lymphoma or cutaneous plasmablastic lymphoma.
Abbreviations: FCL, follicle center lymphoma; ISH, in situ hybridization; WHO, World Health Organization.
TABLE 3 Melanocytic definitions and clinical scenarios
Definitions:
• Nevoid melanoma: lesion of malignant melanocytes with some histologic features which closely mimic architectural and cytologic features of a benign compound or intradermal nevus • Nevoid cutaneous metastatic melanoma: lesion of metastatic malignant melanoma with some histologic features which closely mimic architectural and cytologic features of a benign compound or intradermal nevus • Benign melanocytic nevus: lesion of benign melanocytes with either a compound or intradermal configuration • Atypical blue nevus: lesion of spindled melanocytes with or without an admixed epithelioid component which have any of the following:
pronounced cytologic atypia or hyperchromasia, necrosis, increased mitotic rate or dysmaturation • Blue nevus-like cutaneous metastatic melanoma: lesion of metastatic malignant melanoma composed of spindled and pigmented melanocytes which closely mimic architectural and cytologic features of a benign blue nevus or blue nevus subtype • Blue nevus-like melanoma (malignant blue nevus): lesion of malignant melanocytes which closely mimic architectural and cytologic features of benign blue nevus or arises within a histologically recognizable benign blue nevus remnant • Benign blue nevus: lesion of benign spindled melanocytes occurring within a fibrotic stroma, subtypes include cellular, deep penetrating and epithelioid • Congenital nevus with proliferative nodule: nodular lesion of atypical epithelioid or spindled melanocytes occurring within a preexisting congenital nevus • Atypical Spitz tumor: lesion of Spitzoid melanocytes which have any of the following: marked architectural asymmetry, dysmaturation, ulceration, increased mitotic rate or increased and/or atypical mitoses in the deep portion of the lesion, marked cytologic atypia • Incompletely sampled unclassified Spitz tumor: lesion of Spitzoid melanocytes which is partially sampled to the degree it is not able to be subclassified and with atypical features • Spitzoid melanoma: lesion of malignant melanocytes with some histologic features which closely mimic architectural and cytologic features of a benign Spitz nevus • Sclerosing (desmoplastic) nevus: lesion of benign melanocytes which may be ovoid, dendritic or Spitzoid occurring within a distinctive eosinophilic stroma with overall architectural symmetry and without significant cytologic atypia or mitotic activity • Desmoplastic melanoma: lesion of malignant melanocytes with a predominantly spindled shaped, prominent desmoplasia and frequent neurotropism • Pathology suggestive of/suspicious for melanoma = atypical melanocytic proliferation • Pediatric patient is <18 years of age • Adult patient is ≥18 years of age • Fluorescence in-situ hybridization panel includes:
PRAME a single gene involved in cell differentiation S100A7, S100A8, S100A9, S100A12 and PI3, a group of genes involved in multiple cell signaling pathways CCL5, CD38, CXCL10, CXCL9, IRF1, LCP2, PTPRC and SELL involved in tumor immune response signaling Nine housekeeping genes that are measured to normalize RNA expression for analysis
Clinical scenarios:
1. Adult patient with pathology definitive for melanoma. 2. Adult patient with pathology suggestive or suspicious for melanoma: nevoid melanoma vs benign melanocytic nevus. 3. Adult patient with pathology suggestive or suspicious for melanoma: nevoid cutaneous metastatic melanoma vs benign melanocytic nevus. 4. Adult patient with pathology suggestive or suspicious for melanoma: melanoma arising within a nevus/dysplastic nevus. 5. Adult patient with pathology suggestive or suspicious for melanoma: atypical blue nevus vs benign blue nevus. 6. Adult patient pathology suggestive or suspicious for melanoma: blue nevus-like cutaneous metastatic melanoma vs benign blue nevus. 7. Adult patient with pathology suggestive or suspicious for melanoma: blue nevus-like melanoma (malignant blue nevus) vs benign blue nevus. 8. Adult with pathology suggestive or suspicious for melanoma: congenital nevus with proliferative nodule vs melanoma. 9. Adult patient with pathology suggestive or suspicious for melanoma: atypical Spitz tumor vs Spitzoid melanoma. 10. Adult patient with pathology suggestive or suspicious for melanoma: incompletely sampled unclassified Spitz tumor vs Spitzoid melanoma 11. Adult patient with pathology suggestive or suspicious for melanoma: sclerosing (desmoplastic) nevus incompletely sampled vs desmoplastic melanoma. 12. Adult patient with pathology suggestive or suspicious for melanoma: severely atypical compound melanocytic proliferation vs melanoma on cosmetically sensitive areas and special sites, including digits, acral, genital, ears and scalp 13. Adult patient with pathology definitive for nevus. 14. Distinction of nevus from primary melanoma in an adult patient when the morphologic findings are ambiguous by light microscopic parameters. 15. Distinction of nevus from primary melanoma in an adult patient when the partial nature of the biopsy precludes optimal assessment by light microscopic parameters. 16. Distinction of nevus from metastatic melanoma in an adult patient when the morphologic findings are ambiguous by light microscopic parameters. 17. Distinction of nevus from metastatic melanoma in an adult patient when the partial nature of the biopsy precludes optimal assessment by light microscopic parameters. 18. Pediatric patient with pathology definitive for melanoma. 19. Pediatric patient with pathology suggestive or suspicious for melanoma: nevoid melanoma vs benign melanocytic nevus. 20. Pediatric patient with pathology suggestive or suspicious for melanoma: nevoid cutaneous metastatic melanoma vs benign melanocytic nevus. 21. Pediatric patient with pathology suggestive or suspicious for melanoma: melanoma arising within a nevus/dysplastic nevus. 22 classified as "majority rarely appropriate" (rarely appropriate to uncertain).
During the in-person meeting, panel raters requested 2 additional options be allowed during the rating process: Unqualified (UQ), which was to be used if "as a dermatopathologist I do not have the expertise to decide if this is appropriate" and OUT, which was not an acronym, but rather an indication that "assessment of appropriateness of test cannot be made without direct communication with the clinician and furthermore the appropriateness will change on a case by case basis depending on the clinical information provided." Panel raters were instructed that these 2 options should be used sparingly.
| RESULTS
A total of 211 clinical scenarios were rated. Consensus was reached for 188 (89%) scenarios while no consensus was reached for 23 (11%) scenarios. A consensus of "usually appropriate" was reached in 78 (37%) scenarios with an additional 15 (7%) scenarios where the majority of ratings were usually appropriate ("majority usually appropriate"), consensus of "rarely appropriated" was reached in 45 (21%) scenarios with an additional 7 (3%) scenarios where the majority of ratings were rarely appropriate ("majority rarely appropriate"), while consensus for "uncertain appropriateness" was reached in 43 (20%) scenarios.
Number of times raters used the options "OUT" and "UQ" was recorded in detail during the third round. Important to note, all panel raters felt they had the expertise to rate all clinical scenarios as "UQ" was never used. The use of the "OUT" rating, indicating that consultation with the clinician may be necessary to determine the appropriateness of ordering the ancillary studies, was considered meaningful if ≥3 panel raters used it and only occurred in a total of 9 clinical scenarios. Scenarios that were rated more than once for separate ancillary tests had complementary "OUT" numbers. Tables 8-14 summarize appropriateness ratings for each ancillary study by group.
| DISCUSSION

| Lymphoproliferative group
Additional testing is commonly considered when dealing with a cutaneous lymphoid infiltrate. In examining the literature, evidence for the use of T-cell clonality assays was generally more extensive than that for the B-cell clonality assays.
| TCR clonality assays
Evidence supports the use of both beta and gamma clonality assays, and is reflected in the results with panel raters ranking the appropriateness of beta and gamma clonality similarly for each scenario. T-cell clonality is recommended as a confirmatory test in cases where the histology and immunophenotype are "concerning," "suspicious" or "suggestive of" MF, if a folliculotropic infiltrate is encountered, and for clone comparison. Interestingly, despite the lack of robust literature, experts still ranked the scenario dealing with a T-cell infiltrate in a patient with a history of T-cell lymphoma as "majority usually appropriate." This may be reflective of the knowledge that in some cases of systemic T-cell lymphomas (ie, angioimmunoblastic T-cell lymphoma), secondary cutaneous infiltrates are often not histologically atypical in appearance. In addition, some specialized immunohistochemical stains (ie, PD-1) are not uniformly available in all laboratories. In these cases, TCR clonality assays may be a rapid and inexpensive way to confirm the diagnosis of secondary cutaneous involvement by systemic T-cell lymphoma. Testing would also be a good approach to cases in which the systemic T-cell lymphoma has the TCR in the germline configuration or if the patient has synchronous primary lymphomas.
Congruent with current scientific evidence, testing is "rarely appropriate" in cases of dermatitis or pigmented purpuric patches with a nondiagnostic histology given the inherent limitations in sensitivity and specificity of clonality tests to reliably distinguish between early presentations of T-cell lymphoproliferative disorders and benign inflammatory dermatoses, such as lymphomatoid drug eruptions, lichen sclerosus, entities within the pityriasis lichenoides disease group, and pigmented purpuric eruptions. The high rate of false positives with clonality testing is reflected in the "rarely appropriate" recommendation for the clinical scenarios in which a diagnosis of lymphomatoid papulosis or pityriasis lichenoides is made histologically and the "uncertain appropriateness" recommendation for clinical reactive entities displaying histology and IHC "concerning," "suspicious" or "suggestive of" MF. Not surprisingly, panel raters felt it was "rarely appropriate" to perform this assay in cases of new nodules in a patient with a known diagnosis of MF "concerning,"
"suspicious" or "suggestive of" large cell transformation, regardless of CD30 positivity. Surprisingly, there was "no consensus" to perform clonality studies in the scenario of a new or evolving lesion in a patient with a history of MF where the histology and immunophenotype is "consistent with" MF. It may be inferred that in this clinical scenario, it would be more appropriate to compare clones between the current biopsy and the patients' previous biopsies. Ratings also yielded a recommendation of "no consensus" in the scenario of an erythrodermic patient with 31 . Distinction of nevus from primary melanoma in a pediatric patient when the morphologic findings are ambiguous by light microscopic parameters. 32. Distinction of nevus from primary melanoma in a pediatric patient when the partial nature of the biopsy precludes optimal assessment by light microscopic parameters. 33. Distinction of nevus from metastatic melanoma in a pediatric patient when the morphologic findings are ambiguous by light microscopic parameters. 34. Distinction of nevus from metastatic melanoma in a pediatric patient when the partial nature of the biopsy precludes optimal assessment by light microscopic parameters.
nondiagnostic histology, which may in general reflect poor global experience with early Sézary syndrome.
Although there was 1 clinical scenario where panel raters utilized the "OUT" option during the rating process for both the beta and gamma clonality assays, this was considered to not be significant as rating was completed by 88% of panel raters.
| IgH clonality assay
In looking at the results for B-cell clonality assays, there were 6 clinical scenarios where testing for the rearrangement of the B-cell receptor (IgH) by PCR was "usually appropriate." It is not surprising that testing was found to be "usually appropriate" for scenarios when the histology and immunophenotype of the infiltrate was "concerning • Adult patient: age greater than 14 years
• Pediatric patient: age equal to or less than 14 years
• Condyloma: histopathologic findings to include all of the following: epidermal acanthosis, hyperkeratosis, round parakeratosis, coarse keratohyaline granules, vacuolated keratinocytes, including true koilocytes
• Pathology "suggestive of condyloma": histopathologic findings do not include all of the features defined above for condyloma, and may also include pseudo horn cysts
• Age of 25 was chosen as although seborrheic keratosis have been reported in patients under this age, they are rare and increase in prevalence with increasing age
• Squamous cell carcinoma in situ/ undifferentiated intraepithelial dysplasia of the anogenital skin The terminology used for premalignant and malignant dysplasia of the genitourinary tract has been confusing with older terminology including Bowen's disease, erythroplasia of Queyrat, bowenoid papulosis, multifocal Bowen's disease, severe dysplasia and carcinoma in situ • Newer terminology in the vulva has been replaced with "undifferentiated usual type of vulvar intraepithelial neoplasia (VIN)." This is defined as atypia involving 2/3 to full thickness of the epidermis (previously defined as VIN2 and VIN 3, respectively). VIN1 is not regarded as flat condyloma • The terminology is likewise confusing on the penis, with some proposing a similar nomenclature-undifferentiated PeIN The term used here encompass verrucous carcinoma, well differentiated epidermoid squamous cell carcinoma, epithelioma cuniculatum and giant condyloma of Buschke-Löwenstein that clinically present as a warty, exophytic plaque in the oropharynx, lower limb (typically sole of foot) and anogenital region, respectively. Histopathologic findings should include all the following: exo-endophytic architecture, hyperkeratosis, keratinocytes w/ abundant pale pink cytoplasm, large bulbous rete ridges with pushing boarder
• Subungual wart includes clinical lesions involving the hyponychium, distal nail bed or proximal nail fold that may be causing subungual hyperkeratosis or onycholysis and have histologic findings that include parakeratosis, papillomatosis and the presence of koilocytes in the most superficial layers.
• Verrucous features defined as having any of the following histologic features: epidermal papillomatosis, coarse keratohyaline granules and vacuolated keratinocytes
• HPV-induced lesion of the genital skin includes condyloma or undifferentiated intraepithelial neoplasia
1. Adult patient, pathology definitive for condyloma.
2. Adult patient, pathology suggestive of condyloma.
3. Pediatric patient, pathology definitive for condyloma. 14. Immunosuppressed patients (eg, organ transplant and HIV patients) with squamous cell carcinoma in situ or squamous cell carcinoma with verrucous features.
Abbreviations: LP, lichen planus; LSEA, lichen sclerosus et atrophicus; PeIN, penile intraepithelial neoplasia; SCC, squamous cell carcinoma.
for," "suspicious of" or "suggestive of" either primary cutaneous marginal zone lymphoma (PCMZL) or follicle center lymphoma (FCL).
These entities tend to be difficult to diagnose based primarily on histology or immunohistochemistry. In PCMZL, definitive diagnosis often relies on detection of light chain restriction which can be difficult unless plasma cells are abundant. In FCL, the typical histologic features relied on by hematopathologists such as back-to-back follicle formation or bcl-2 expression are often absent even in grade 2 FCL.
While in FCL with a diffuse pattern, the presence of sheets of B-cells is concerning for lymphoma, again, lack of typical follicular lymphoma markers such as expression of CD10 and bcl-2 can lead to confusion even among experienced dermatopathologists. In these scenarios, testing with clonality assays can confirm the diagnosis. 9 As expected, testing was "usually appropriate" in cases where the clonality assay :
• Age 60: there are some articles that suggest age 50 instead of 60 as a cut off, this may be because sebaceous neoplasms present at a mean age of 53 • MTS-associated sebaceous neoplasm: sebaceous adenoma, sebaceoma, sebaceous epithelioma and sebaceous carcinoma • MTS-associated neoplasm: MTS-associated sebaceous neoplasms, cystic sebaceous neoplasm, basal cell carcinoma with sebaceous differentiation and keratoacanthoma with sebaceous differentiation • MTS-associated visceral malignancy: colorectal adenocarcinoma (most common), genitourinary carcinoma (second most common), breast, hematologic and endometrial and gastric carcinoma (less common)
1. A patient over the age of 60 with a periocular sebaceous carcinoma. 2. A patient over the age of 60 with a single sebaceous tumor on the head and neck. 3. A patient over the age of 60 with a single sebaceous tumor on a site other than the head and neck. 4. A patient over the age of 60 with multiple (greater than or equal to 2) sebaceous tumors. 5. A patient over the age of 60 with a basal cell carcinoma with sebaceous differentiation. 6. A patient over the age of 60 with a keratoacanthoma with sebaceous differentiation. 7. A patient over the age of 60 with a cystic sebaceous neoplasm. 8. A patient over the age of 60 with an MTS-associated neoplasm and/or a personal history of an MTS-associated visceral malignancy.
TABLE 6 Definitions and clinical scenarios for dermatofibrosarcoma protuberans
• Typical histomorphology of DFSP: monotonous spindled cells in a storiform pattern with "honeycombing" or entrapment of adnexal structures and/or adipocytes and extension into the subcutis
• Nontypical histomorphology of DFSP refers to variant histomorphology such as fibrosarcomatous, giant cell fibroblastoma, myxoid, epithelioid or nonspecific spindled cell histomorphology.
1. Tissue with sampling down to subcutis with typical histomorphology of dermatofibrosarcoma protuberans and CD34+ by immunohistochemistry.
2. Tissue with sampling down to subcutis with typical histomorphology of dermatofibrosarcoma protuberans and CD34 immunohistochemistry not uniformly reactive.
3. Tissue with sampling down to subcutis with nontypical histomorphology of dermatofibrosarcoma protuberans and CD34+ by immunohistochemistry.
4. Superficial, CD34+ tumor with typical histomorphology of dermatofibrosarcoma protuberans except that good honeycombing of fat is not seen due to superficial sampling.
Superficial, CD34+ tumor with nontypical histomorphology for dermatofibrosarcoma protuberans. (SD5)
6. Superficial, CD34+ tumor with scant tumor sampling as to limit cytologic and/or architectural evaluation.
7. High grade spindle cell tumor ("fibrosarcomatous transformation") and no areas of typical histomorphology of dermatofibrosarcoma protuberans.
8. Metastatic tumor with histomorphology similar to previously diagnosed primary dermatofibrosarcoma protuberans.
9. Metastatic tumor with histomorphology distinct from previously diagnosed primary dermatofibrosarcoma protuberans. 12. Patients for which tyrosine kinase therapy is being considered in the treatment plan.
13. Patient with tissue that has been decalcified or processed with fixative other than 10% formalin.
14. Patient with a pathologic diagnosis of dermatofibrosarcoma protuberans by hematoxylin and eosin with CD34+ immunohistochemistry but where the treating physician is requesting molecular studies (RT-PCR, FISH and cytogenetics) to be performed to further confirm the diagnosis. similar across age groups (adult vs pediatric). In most scenarios, except for those where the pathology is definitive for melanoma or melanocytic nevus, expert rating found that it is "usually appropriate"
to perform FISH or CGH on melanocytic lesions when the diagnosis is in question. In those cases where the pathology is definitive for either a melanoma or melanocytic nevus, testing with FISH and CGH is "rarely appropriate." This was not surprising as histology is considered the "gold standard" in the diagnosis of melanocytic lesions. Of note, inclusion of these clinical scenarios may be considered a proof of concept that the rounds of ratings yielded meaningful results.
Interestingly, the results also indicate that currently CGH is the only test ranked "usually appropriate" when it comes to distinguishing benign blue nevi from more worrisome dermal melanocytoses. The 13. Patient with primary or metastatic tumor expressing melanocytic markers in which BRAF or NRAS mutation has been detected.
14. Patient with tissue that has been decalcified or processed with fixative other than 10% formalin. consensus rating for FISH in the same clinical scenario was of uncertain appropriateness. Pouryazdanparast et al described the utility in epithelioid blue nevi and cutaneous melanoma metastases simulating blue nevi 15 and Gammon et al explored FISH in distinguishing cellular blue nevi from blue nevus-like melanoma showing 100% sensitivity and specificity. 16 While these studies utilized a FISH probe set different from the one defined by the group in this analysis, there was overlap of at least of 2 of the probes used-the RREB1 and 6p25
probes. There was "no consensus" on the value of FISH for situations where the pathology is suggestive or suspicious for melanoma where the differential diagnosis is between sclerosing desmoplastic nevus and desmoplastic melanoma, in partially sampled lesions. However, in this specific scenario, CGH was rated "usually appropriate." This may relate to Gerami et al in 2011, which showed a low sensitivity but high specificity in this subset with FISH. 17 The "OUT" rating was used once in 3 clinical scenarios by the panel raters when rating FISH and CGH, with 94% of panel raters participating. Scenarios rated for FISH and CGH independently showed the same number of "OUT" ratings and when they were considered in pediatric vs adult patients the use of "OUT" was similar.
| Quantitative reverse transcription polymerase chain reaction
Consensus ratings in most of the clinical scenarios using qRT-PCR were of "appropriateness uncertain" with the exception being those cases where a diagnosis can be made on histologic grounds. While validation studies and studies exploring unequivocal cases had been published when the AUC process began, 18, 19 only one study was available exploring the test in ambiguous lesions 20 at the time of rating. In addition, the possibility of limited clinical experience with the test may have played a role in the rating result. Since the completion of the AUC process, additional studies have been reported in the literature, including one dealing with diagnostically challenging cases 21 and another that correlates with clinical outcome. Although there are many commercially available type-specific probes and "cocktails" for the detection of HPV by ISH, type-specific probes for HPV 6, 11, 16, 18, 31 and 33 are the most commonly utilized by dermatopathologists. The availability of commercially available antibodies targeting HPV is much more limited, with only 2 currently available.
11
While most of the literature for detection of HPV centers on use of ISH in condylomas or lesions histologically concerning for condylomas in adults, consensus ratings found testing by ISH to be "rarely appropriate" to "majority rarely appropriate" for many scenarios ranked. Only in pediatric cases where pathology is suggestive of condyloma, did experts feel testing by ISH was "usually appropriate." Literature on this topic suggests that sensitivities for detection of HPV by ISH in the pediatric population ranges from 60% to 100%, [23] [24] [25] [26] which may be the reason for the recommendation. However, there was "no consensus" in a similar scenario of a pediatric patient, but with histology definitive for condyloma. This rating may be because HPV 2, which is not typically detected by ISH, is the most common subtype of HPV found in this age group. 27 Most scenarios were ranked as "rarely appropriate" for the use of IHC in the detection of HPV. These ratings probably reflect the Table 3 for complete wording of the clinical scenarios and associated definitions.
Abbreviations: bx, biopsy; CGH, comparative genomic hybridization; cut, cutaneous; cong, congenital; DDx, differential diagnosis; FISH, florescence in situ hybridization; MM, melanoma; mel, melanocytic; met, metastasis; prolif, proliferative; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SS, special sites; vs, versus; w/ in, within. Usually appropriate indications (UA; mean' scores of ≥7.0) are colored dark green; Usually appropriate to uncertain ("majority usually appropriate") indications (UAU; mean' scores between 6.1 and 6.9 and SD <2. 
30-32
The average age of presentation of sebaceous neoplasms in MTS is 53 years old; however, the range is broad . Of note, these neoplasms can present before (22%), concurrently with (6%) or after (56%) the internal malignancy. 33 were also found to be "usually appropriate" following the rounds of expert rating. Interestingly, the "OUT" option was not used frequently in the rating of these clinical scenarios. or COL1A1 break-apart FISH. [35] [36] [37] [38] [39] [40] The overall sensitivity of the dualfusion FISH test in the literature is 94.3% (range 86%-100%). This was similar for PDGFB break-apart FISH that has an overall sensitivity of 95% (range 91%-100%). The sensitivity of the COL1A1 break-apart probe is probably in the same range; however, there is only one study that explicitly mentioned this probe being identified. [41] [42] [43] [44] Given the high sensitivity of FISH and the therapy potential if the translocation is detected, it is not surprising that the two scenarios where the test Tissue that has been decalcified or processed w/ fixative other than 10% formalin UA (7.0) *Refer to Table 7 for complete wording of the clinical scenarios and associated definitions.
Abbreviations: CCS, clear cell sarcoma; Hx, history; MM, malignant melanoma; Met, metastatic; SQ, subcutis; typical histology, tumor with a distinctly nested growth pattern that is divided by fibrous septations. Cells have a relatively uniform nucleus and large central nucleoli. Scattered osteoclast-like giant cells can be seen. There is little to no melanin appreciated; typical location, deep soft tissue of tendon, aponeuroses and fascial structures of the distal extremities; w/, with. Usually appropriate indications (UA; mean' scores of ≥7.0) are colored dark green; Usually appropriate to uncertain ("majority usually appropriate") indications (UAU; mean' scores between 6.1 and 6.9 and SD <2.0) are colored light green; Rarely appropriate indications (RA; mean' scores of ≤3.0) are colored dark red; Rarely appropriate to uncertain (majority rarely appropriate) indications (RAU; mean' scores between 3.1 and 3.9 and SD <2.0) are colored light red; Uncertain appropriateness indications (U; mean' scores of ≥4.0 and ≤ 6.0 with a SD <2.0) are colored blue; No consensus (NC; mean' scores between 3.1 and 6.9 that had a SD ≥2.0) are colored white.
was found to be "usually appropriate" were situations when the histology of the tumor is not typical for DFSP and the tumor is CD34 reactive and situations where tyrosine kinase therapy is being considered.
The scenarios where the histology is not typical for DFSP and the tumor is CD34 reactive but the subcutis is not visualized were found to be "majority usually appropriate." Although this may suggest a bias from panel raters, that it may be more appropriate to discuss the case with the clinician and depending on clinical circumstances obtain a larger sample of the tumor to visualize deeper structures, this was not reflected using the "OUT" option. The frequent use of the "OUT" option (44% of panel raters) in the scenario where the sample provided for evaluation is limited both cytologically and architecturally probably underscores the importance of a discussion to ascertain the feasibility of obtaining more tissue prior to performing the test. The lack of consensus for this scenario is thus not surprising. Similarly, this may be the case when the tissue has not been processed in a standard manner because these tumors are usually large and accessible.
Interestingly, expert ratings found it "majority usually appropriate" to perform FISH in scenarios when only fibrosarcoma-like areas are visualized and when the clinician is requesting further confirmation of the diagnosis. Perhaps, the latter recommendation by panel raters considers that the clinician may be planning to use targeted therapy and is also reflected by three panel raters using the "OUT"
option. Conversely, it is not surprising that results show testing to be "rarely appropriate" when the histology and IHC are supportive for a diagnosis of DFSP, a metastatic lesion is encountered with a similar histology to a prior DFSP, or in situations where testing for the translocation has been completed by another testing modality.
Although overall the "OUT" option was not used frequently for scenarios dealing with the use of FISH in the diagnosis of DFSP, there was one scenario in this group that had the highest number of "OUT" ratings of all 211 clinical scenarios. This was the scenario dealing with utility of the test in cases where the tissue available for evaluation is limited.
| EWSR1 FISH assay for CCS
CCS is a very rare aggressive soft tissue sarcoma showing neuroectodermal and melanocytic differentiation. 45, 46 It typically occurs in individuals <50 years of age and preferentially arises in the deep soft tissue of distal extremities. Although it shares some histologic overlap with melanoma, it is genetically and biologically distinct, resulting in prognostic differences. 47, 48 As there are significant consequences for misdiagnosis of CCS, it follows that expert rating found it "usually appropriate" to perform the dual-color break-apart EWSR1 FISH assay in cases where a histology typical of CSS is encountered, especially given the test's high specificity of 97.91%. 49 This rating holds true regardless of age and if an intraepidermal component is found histologically. Additionally, testing is "usually appropriate" when a metastatic lesion is encountered in a patient with a previously diagnosed CCS, but the histology of the metastatic lesion appears distinct, and for situations where CCS is suspected, but the specimen was not fixed in standard fixative or decalcified. The majority of the panel raters would also do testing despite a BRAF or NRAS mutation having already been detected in either a primary or metastatic lesion. For clinical scenarios where a typical histology of CCS is lacking, older individuals and occurrence of CCS on nontypical locations testing for EWSR1 FISH was generally not recommended ("majority rarely appropriate"/"rarely appropriate"). Likewise, testing was "rarely appropriate" if the tumor has undergone testing to detect the translocation by another modality.
| Overall conclusions
This paper summarizes the first set of AUC in dermatopathology and represents the first AUC developed for pathology and the second AUC developed for dermatology using the RAND/UCLA methodology. The intent of these AUC is to provide guidance and clarification for use of a test in a particular clinical scenario. Although some of the scenarios specifically address adequacy of the sampled specimen, discretion and clinical judgment should be used regarding suitability of the test for a specific specimen. These guidelines may provide the foundation for studies exploring over and under use of tests/ancillary studies and serve as a model for further efforts in the field.
Evidence review was at the crux of expert judgment in ranking each scenario. Therefore, as new literature emerges, AUC developed here will need to be updated and may be revised. Importantly, scenarios that resulted in "no consensus" and consensus around "uncertain appropriateness" are areas where the body of evidence is controversial and/or underdeveloped. It is the hope that in addition to providing a guide for those using these tests/procedures for diagnosis of skin biopsy specimens, that the results of this process will also highlight the areas of needed and potential research.
The concept of appropriate and necessary care is essential for a healthcare system to be efficient and just. The development and implementation of AUC is necessary to address ambiguous approaches in utilizing ancillary studies with policy makers, healthcare organizations and the public.
